Cellectis (CLLS) Income from Continuing Operations (2015 - 2026)
Cellectis (CLLS) posted quarterly Income from Continuing Operations of 8784000.0 for Q1 2026, down 471.42% year-over-year from 2365000.0 in Q1 2025, and up 91.68% quarter-over-quarter from 105544000.0 in Q4 2025.
Powered by 
Analysis
Cellectis (CLLS) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Cellectis' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 8784000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 471.42% year-over-year to 8784000.0; the TTM figure through Mar 2026 stood at 76262000.0 (down 34.18% YoY), while the FY2025 annual figure was 67593000.0, down 83.87% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 8784000.0, up from 105544000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 22412000.0 in Q3 2025, with the low at 105544000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 8784000.0 (2026), against an average of 18271823.53.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 3125.31% in 2023, then soared 193.27% in 2025.
- Cellectis' Income from Continuing Operations stood at 2750000.0 in 2022, then plunged by 3125.31% to 88696000.0 in 2023, then surged by 53.61% to 41149000.0 in 2024, then tumbled by 156.49% to 105544000.0 in 2025, then soared by 91.68% to 8784000.0 in 2026.
- Business Quant data shows CLLS's Income from Continuing Operations at 8784000.0 in Q1 2026, 105544000.0 in Q4 2025, and 22412000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -15.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.75 Mn |
| Mar 31, 2026 | -8.78 Mn |
| Dec 31, 2025 | -3.42 Mn |
| Sep 30, 2025 | 22.41 Mn |
| Jun 30, 2025 | 15.65 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | -37.78 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | -25.31 Mn |
| Mar 31, 2024 | 11.39 Mn |
| Dec 31, 2023 | -118.06 Mn |
| Sep 30, 2023 | -546,000.00 |
| Jun 30, 2023 | 4.48 Mn |
| Mar 31, 2023 | -21.88 Mn |
| Dec 31, 2022 | -2.75 Mn |
| Sep 30, 2022 | -23.37 Mn |
| Jun 30, 2022 | -19.01 Mn |
| Mar 31, 2022 | -5.62 Mn |
| Dec 31, 2021 | -7.06 Mn |
| Sep 30, 2021 | -42.37 Mn |